| scholarly article | Q13442814 |
| P50 | author | Maria B Grant | Q88523403 |
| P2093 | author name string | Kirk P Conrad | |
| J Peter Rubin | |||
| Laura Sautina | |||
| Mark Segal | |||
| Jacqueline Novak | |||
| Jonathan T McGuane | |||
| Julianna E Debrah | |||
| Yagna P R Jarajapu | |||
| P2860 | cites work | Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation | Q22010150 |
| Activation of orphan receptors by the hormone relaxin | Q24292229 | ||
| Relaxin family peptide receptors RXFP1 and RXFP2 modulate cAMP signaling by distinct mechanisms | Q24311590 | ||
| Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase | Q28115936 | ||
| Key role of alpha(1)beta(1)-integrin in the activation of PI3-kinase-Akt by flow (shear stress) in resistance arteries | Q28576516 | ||
| A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) | Q28640016 | ||
| The G beta gamma sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101 | Q28678835 | ||
| Fluorescent Indicators for Imaging Nitric Oxide Production. | Q30810786 | ||
| Recent progress in heart failure treatment and heart transplantation | Q33385850 | ||
| Characterizing the interactions between the two subunits of the p101/p110gamma phosphoinositide 3-kinase and their role in the activation of this enzyme by G beta gamma subunits | Q33864082 | ||
| A novel phosphoinositide 3 kinase activity in myeloid-derived cells is activated by G protein beta gamma subunits | Q34339415 | ||
| Relaxin-induced increased coronary flow through stimulation of nitric oxide production. | Q35872760 | ||
| Modulation of the L-arginine/nitric oxide signalling pathway in vascular endothelial cells | Q36074184 | ||
| Unveiling the vasodilatory actions and mechanisms of relaxin | Q36084530 | ||
| Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor? | Q36357265 | ||
| Age impairs Flk-1 signaling and NO-mediated vasodilation in coronary arterioles | Q37038750 | ||
| Relaxin, a pleiotropic vasodilator for the treatment of heart failure. | Q37356318 | ||
| Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells | Q37358571 | ||
| Role of relaxin in maternal systemic and renal vascular adaptations during gestation | Q37470800 | ||
| Relaxin family peptide receptor (RXFP1) coupling to G(alpha)i3 involves the C-terminal Arg752 and localization within membrane Raft Microdomains. | Q38358685 | ||
| MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo | Q38431323 | ||
| Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. | Q39305717 | ||
| Phosphoinositide 3-kinase activity is required for biphasic stimulation of cyclic adenosine 3',5'-monophosphate by relaxin | Q40669315 | ||
| Acylation targets emdothelial nitric-oxide synthase to plasmalemmal caveolae | Q41215934 | ||
| Relaxin stimulates expression of vascular endothelial growth factor in normal human endometrial cells in vitro and is associated with menometrorrhagia in women | Q41648760 | ||
| Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial. | Q42616224 | ||
| SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types | Q42820704 | ||
| The pregnancy hormone relaxin is a player in human heart failure. | Q43771271 | ||
| Rapid transactivation of the vascular endothelial growth factor receptor KDR/Flk-1 by the bradykinin B2 receptor contributes to endothelial nitric-oxide synthase activation in cardiac capillary endothelial cells | Q43801362 | ||
| Is the pregnancy hormone relaxin also a vasodilator peptide secreted by the heart? | Q44064950 | ||
| Role of phospholipase C in development of myogenic tone in rat posterior cerebral arteries | Q44185505 | ||
| Essential Role for Vascular Gelatinase Activity in Relaxin-Induced Renal Vasodilation, Hyperfiltration, and Reduced Myogenic Reactivity of Small Arteries | Q44639210 | ||
| Role of phosphatidylinositol-3-kinase and protein kinase C zeta in the adenylate cyclase signal mechanism of action of relaxin in muscle tissues of rats and mollusks | Q45235176 | ||
| Estrogen induces vascular wall dilation: mediation through kinase signaling to nitric oxide and estrogen receptors alpha and beta. | Q45967050 | ||
| Chemistry and biology of wortmannin | Q46511165 | ||
| On the specificity of 4-amino-5-methylamino-2',7'-difluorofluorescein as a probe for nitric oxide | Q46579553 | ||
| Evidence for local relaxin ligand-receptor expression and function in arteries. | Q51778307 | ||
| Influence of recombinant human relaxin on renal hemodynamics in healthy volunteers. | Q51780967 | ||
| Disruption of endothelial caveolae is associated with impairment of both NO- as well as EDHF in acetylcholine-induced relaxation depending on their relative contribution in different vascular beds. | Q52577443 | ||
| Gbetagamma stimulates phosphoinositide 3-kinase-gamma by direct interaction with two domains of the catalytic p110 subunit. | Q52995859 | ||
| Effects of human relaxin on isolated rat and human myometrium and uteroplacental arteries | Q68018310 | ||
| Effect of porcine relaxin on the human umbilical artery | Q68890727 | ||
| Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor | Q73175870 | ||
| Determination and bioimaging method for nitric oxide in biological specimens by diaminofluorescein fluorometry | Q73286652 | ||
| Myogenic reactivity is reduced in small renal arteries isolated from relaxin-treated rats | Q74472216 | ||
| Ghrelin has novel vascular actions that mimic PI 3-kinase-dependent actions of insulin to stimulate production of NO from endothelial cells | Q79359834 | ||
| The low-density lipoprotein class A module of the relaxin receptor (leucine-rich repeat containing G-protein coupled receptor 7): its role in signaling and trafficking to the cell membrane | Q79421900 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2786-2796 | |
| P577 | publication date | 2011-05-10 | |
| P1433 | published in | Endocrinology | Q3054009 |
| P1476 | title | Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide | |
| P478 | volume | 152 |
| Q34226848 | A vasoactive role for endogenous relaxin in mesenteric arteries of male mice |
| Q37648577 | Acute intravenous injection of serelaxin (recombinant human relaxin-2) causes rapid and sustained bradykinin-mediated vasorelaxation. |
| Q33982388 | Acute treatment with relaxin protects the kidney against ischaemia/reperfusion injury |
| Q38850557 | Anti-fibrotic actions of relaxin. |
| Q26853363 | Cardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction |
| Q37942485 | Effects of relaxin on arterial dilation, remodeling, and mechanical properties |
| Q38238450 | Emerging role of serelaxin in the therapeutic armamentarium for heart failure |
| Q36506903 | Enhanced serelaxin signalling in co-cultures of human primary endothelial and smooth muscle cells |
| Q26744192 | G-Protein-coupled receptors as potential drug candidates in preeclampsia: targeting the relaxin/insulin-like family peptide receptor 1 for treatment and prevention |
| Q36380039 | GPCRs as potential therapeutic targets in preeclampsia. |
| Q40958055 | Increased superoxide production and altered nitric oxide-mediated relaxation in the aorta of young but not old male relaxin-deficient mice. |
| Q35383835 | International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides. |
| Q37083919 | Involvement of Cyclic Guanosine Monophosphate-Dependent Protein Kinase I in Renal Antifibrotic Effects of Serelaxin |
| Q37405208 | Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin-mediated relaxation after in vivo serelaxin treatment |
| Q33774441 | ML290 is a biased allosteric agonist at the relaxin receptor RXFP1. |
| Q24618633 | Maternal vasodilation in pregnancy: the emerging role of relaxin |
| Q42696155 | Newer drugs for heart failure: hype or hope? |
| Q52674866 | Oxidative Stress and Renal Fibrosis: Recent Insights for the Development of Novel Therapeutic Strategies. |
| Q30251531 | Potential new drug treatments for congestive heart failure |
| Q36797528 | Protection from cigarette smoke-induced vascular injury by recombinant human relaxin-2 (serelaxin) |
| Q58764679 | RXFP1 Receptor Activation by Relaxin-2 Induces Vascular Relaxation in Mice a Gα-Protein/PI3Kß/γ/Nitric Oxide-Coupled Pathway |
| Q49922719 | Recombinant Relaxin Protects Liver Transplants from Ischemia Damage via Hepatocyte Glucocorticoid Receptor: From Bench-to-Bedside. |
| Q38220684 | Recombinant human relaxin-2: (how) can a pregnancy hormone save lives in acute heart failure? |
| Q28550653 | Relaxin Treatment in an Ang-II-Based Transgenic Preeclamptic-Rat Model |
| Q55209012 | Relaxin as a Therapeutic Target for the Cardiovascular Complications of Diabetes. |
| Q32178607 | Relaxin attenuates aristolochic acid induced human tubular epithelial cell apoptosis in vitro by activation of the PI3K/Akt signaling pathway |
| Q38719444 | Relaxin confers cytotrophoblast protection from hypoxia-reoxygenation injury through the phosphatidylinositol 3-kinase-Akt/protein kinase B cell survival pathway |
| Q46586252 | Relaxin deficiency attenuates pregnancy-induced adaptation of the mesenteric artery to angiotensin II in mice. |
| Q35141812 | Relaxin does not improve Angiotensin II-induced target-organ damage. |
| Q35669250 | Relaxin increases human endothelial progenitor cell NO and migration and vasculogenesis in mice |
| Q36252373 | Relaxin mediates uterine artery compliance during pregnancy and increases uterine blood flow |
| Q47966144 | Relaxin modulates human and rat hepatic myofibroblast function and ameliorates portal hypertension in vivo |
| Q35108756 | Relaxin regulates vascular wall remodeling and passive mechanical properties in mice |
| Q34398874 | Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS. |
| Q38853366 | Relaxin treatment reduces angiotensin II-induced vasoconstriction in pregnancy and protects against endothelial dysfunction†. |
| Q37110579 | Relaxin treatment reverses insulin resistance in mice fed a high-fat diet |
| Q41463324 | Relaxin-2 in Cardiometabolic Diseases: Mechanisms of Action and Future Perspectives |
| Q38373223 | Relaxin: a novel agent for the treatment of acute heart failure |
| Q38080804 | Relaxin: new pathophysiological aspects and pharmacological perspectives for an old protein |
| Q38383238 | Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin |
| Q38215304 | Serelaxin : a potential new drug for the treatment of acute heart failure |
| Q37368923 | Serelaxin Elicits Bronchodilation and Enhances β-Adrenoceptor-Mediated Airway Relaxation. |
| Q37712528 | Serelaxin Treatment Reduces Oxidative Stress and Increases Aldehyde Dehydrogenase-2 to Attenuate Nitrate Tolerance. |
| Q38646840 | Serelaxin and acute heart failure |
| Q36292811 | Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial |
| Q34726868 | Serelaxin reduces oxidative stress and asymmetric dimethylarginine in angiotensin II-induced hypertension |
| Q35039209 | Serelaxin-mediated signal transduction in human vascular cells: bell-shaped concentration-response curves reflect differential coupling to G proteins |
| Q48331109 | Short-term (48 hours) intravenous serelaxin infusion has no effect on myogenic tone or vascular remodeling in rat mesenteric arteries |
| Q52851745 | The actions of relaxin on the human cardiovascular system. |
| Q27003301 | The renal circulation in normal pregnancy and preeclampsia: is there a place for relaxin? |
| Q37686150 | Time-dependent activation of prostacyclin and nitric oxide pathways during continuous i.v. infusion of serelaxin (recombinant human H2 relaxin) |
| Q38945156 | Vascular actions of relaxin: nitric oxide and beyond |
Search more.